04.04.2017 • TopicsDr. Gerd BergmannNordmannNRC

Open to New Ways of Doing Business

Christopher Erbslöh, managing director, C.H. Erbsloeh
Christopher Erbslöh, managing director, C.H. Erbsloeh

“Today’s digital transformation debate bewilders me somewhat, as this is not a new topic but one that has been around for more than 40 years. The only difference is the speed at which new and updated technology is available. Today, as back in the 1970s, the only right answer to the digital transformation debate is: “Yes, we should introduce and use any new technology that advances our business at a justifiable cost.”

For specialty distributors like C.H. Erbslöh we expect positive effects from new technologies mainly in administrative processes but also in the supply chain. We, however, neither see our workforce being reduced nor a full transformation of our point of sales to an e-commerce platform in the next 5 to 8 years. Having said that, it is obvious that some product categories surely will be sold through e-commerce platforms in the near future. Still, we do not have a special digital agenda as new ideas, technologies and ways of doing business always have been on our agenda.”

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.